

11 October 2024

Drugs used to treat Inflammatory Diseases

Q1a – How many patients were treated with the following drugs for the following diseases from the start of Apr 2024 to the end of Jun 2024?

Please use the latest available 3 months if April to June is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab	221	*	*	374	223	204
Apremilast	8			0		
Bimekizumab	13			0	0	
Brodalumab	0					
Certolizumab Pegol	8			55	21	25
Deucravacitinib	1					
Etanercept	4			134	70	170
Guselkumab	88			4		
Infliximab (Remicade)	1	*	*	15	10	11
Infliximab (Biosimilars)	1	*	*	12	10	11
Ixekizumab	63			241	155	
Risankizumab	98	*		0		
Secukinumab	38			148	53	
Tildrakizumab	5					
Ustekinumab	71	*	*	8		
Upadacitinib		*	*	15	11	44
Vedolizumab		*	*			
Filgotinib			*			
Golimumab			*	50	23	12
Mirikizumab			*			
Ozanimod			*			
Etrasimod			*			
Tofacitinib			*	5	1	9
Baricitinib						0
Rituximab						0
Sarilumab						0
Tocilizumab						0

11 October 2024

Q1b – How many patients were treated with Ustekinumab and its biosimilars from the start of Jun 2024 to the end of Aug 2024?

Please use the latest available 3 months if June to August is not available and specify which 3 months has been used.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis
Ustekinumab (Stelara)	71	*	*	1
Ustekinumab (Pyzchiva)	0	*	*	0
Ustekinumab (Uzpruvo)	0	*	*	0
Ustekinumab (Wezenla)	0	*	*	0

* The information relating to Crohn's Disease and Ulcerative Colitis is not held in a way which would allow us to retrieve this data easily, this is due to the way these records are held on our new IT system Encompass. This is being addressed. To provide this information would require a manual trawl through patient records and would exceed the 18 hour limit.

Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.